Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor + bortezomib + lenalidomide + dexamethasone for newly diagnosed high-risk multiple myeloma
ChiCTR2200062860Phase 4Recruiting
- Sponsor
- Qingdao Municipal Hospital
- Start
- Aug 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of selinexor, bortezomib, lenalidomide and dexamethasone in multiple myeloma (MM) and plasma cell leukaemia (PCL), sponsored by Qingdao Municipal Hospital. Primary endpoints: Objective remission rate and Minimal residual disease negative rate. Started Aug 2022; status: recruiting.
02
Drugs
selinexorbortezomiblenalidomidedexamethasone
03
Conditions
multiple myeloma (MM)plasma cell leukaemia (PCL)
Beyond the preview
Go deeper on ChiCTR2200062860.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200062860.